Skip to main content

Rolf Muller

BioFluidica has appointed Rolf Muller as CEO. He will assume responsibilities immediately and will succeed Steven Soper, who will remain the company’s chief technology officer. BioFluidica develops technologies for the isolation and analysis of rare, circulating biomarkers in the blood. The company's first platform is being used analyze liquid biopsies to isolate circulating tumor cells and other rare cells from the blood. Prior to joining BioFluidica, Muller was the cofounder and president of Biomatrica. 

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.